Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2012



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)


Organizer(s) Sam Gandy, Steven T. DeKosky and Ann C. McKee
February 26—March 2, 2012
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Oct 26, 2011
Late Abstract Deadline: Dec 2, 2011
Scholarship Deadline: Oct 26, 2011
Early Registration Deadline: Jan 4, 2012

Supported by the Directors’ Fund


Summary of Meeting:
Acute traumatic brain injury (TBI) and its long-term neurodegenerative complications (known collectively as chronic traumatic encephalopathy, or CTE) are increasingly recognized as major public health issues, especially in the context of sports-related head injury and battlefield blast (military) exposure. Awareness of these issues has risen as neurological, psychiatric and neurodegenerative phenomena are associated with professional athletes and with veterans returning from Iraqi and Afghan theaters. The physics of head injury, as well as the epidemiological and neuropsychiatric aspects of sports-related and blast-related syndromes, will be reviewed in the initial sessions of this three-day meeting. Advances in functional neuroimaging and in the rapid and convenient determination of peptides and proteins in the cerebrospinal fluid and plasma will be reviewed in terms of their possible pathobiological significance as well as their identities as possible biomarkers. Later sessions will focus on the overlap between CTE and major neurodegenerative diseases, such as Alzheimer’s Disease (AD), frontotemporal dementia and amyotrophic lateral sclerosis. CTE is associated with accumulation of aggregated proteins or protein fragments, including tau, TDP-43, the Alzheimer’s amyloid precursor protein (APP) and the APP metabolite, amyloid-b. New experimental therapeutics research targets the roles these abnormal protein structures play in injury severity and subsequent outcome. Ab-lowering medications, currently in clinical trials for AD, improve outcome following acute brain trauma in rodent models, suggesting a pathway toward potential therapeutic interventions. Because apolipoprotein E (ApoE) isotype is an important determinant of outcome from acute severe as well as mild repetitive TBI, this meeting coincides in time and venue with the Keystone Symposia meeting on ApoE, Alzheimer’s and Lipoprotein Biology. Opening plenary sessions and an optional fourth day of sessions are available for those interested in learning more about basic biology and/or clinical interventions related to APOE.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, FEBRUARY 26

15:00—19:30
Registration

Longs Peak Foyer
18:15—19:15
Refreshments

Longs Peak
19:15—21:30
Welcome and Keynote Session (Joint)
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Joachim Herz, University of Texas Southwestern Medical Center, USA

* David M. Holtzman, Washington University, USA

* Eric M. Parker, Synergy Partners R&D Solutions, USA

Robert W. Mahley, J. David Gladstone Institutes, USA
Neurobiology of Apolipoprotein E in Alzheimer’s Disease and Traumatic Brain Injury

Robert C. Malenka, Stanford University School of Medicine, USA
Molecular Mechanisms of Synaptic Plasticity


MONDAY, FEBRUARY 27

07:00—08:00
Breakfast

Longs Peak
08:00—08:15
Welcoming Remarks

Grays I
* Sam Gandy, Mount Sinai Medical Center, USA

* Steven T. DeKosky, University of Virginia, USA

* Ann C. McKee, Boston University / VA Boston Healthcare System, USA

08:15—11:30
Definition of the Problem: Epidemiology of Sports and Military TBI
Meeting has ended...abstracts no longer viewable online.

Grays I
* Sam Gandy, Mount Sinai Medical Center, USA

Steven T. DeKosky, University of Virginia, USA
Traumatic Brain Injury: Multiple Causes, and Short and Long-Term Consequences

Andrew I. R. Maas, Antwerp University Hospital - UZA, Belgium
Definition and Epidemiology in TBI

Kevin M. Guskiewicz, University of North Carolina, USA
Clinical Spectrum of Sports TBI

Victoria E. Johnson, University of Pennsylvania, USA
Short Talk: Persistent Inflammation in the Corpus Callosum for Many Years following a Single TBI in Humans

Jenna M. Ziebell, University of Arizona, USA
Short Talk: Morphological Alignment of Microglia across Cortical Layers after Experimental Diffuse Brain Injury

Ramesh C. Nayak, MSDx Inc, USA
Short Talk: Recirculating Phagocytes are a Novel Source of Biomarkers for Brain Injury

Sarah C. Hellewell, National Trauma Research Institute, Monash University, Australia
Short Talk: EPO Ameliorates Axonal Damage, Attenuates Macrophage Infiltration and Restores Motor Function in a Combined Model of TAI and Hypoxia

08:00—11:15
ApoE and ApoE Receptors - Structure, Function and Genetics
Meeting has ended...abstracts no longer viewable online.

Grays II & III
* Robert W. Mahley, J. David Gladstone Institutes, USA

Yadong Huang, Gladstone Institutes and University of California, San Francisco, USA
ApoE4 Structure–Related Detrimental Effects and Structure Correctors

Guojun Bu, Mayo Clinic, USA
ApoE Receptor LRP1 in Brain Lipid Metabolism, Synaptic Functions and Abeta Clearance

Carlos Cruchaga, Washington University School of Medicine, USA
What Do Genetic Studies Tell Us about the Role of APP and APOE in Risk for AD?

Eric Reiman, Banner Alzheimer's Institute, USA
Brain Imaging and ApoE4 in the Presymptomatic Study and Treatment of Alzheimer's Disease

Thomas L. Kukar, Emory University, USA
Short Talk: Lysine 624 of the Amyloid Precursor Protein (APP) is a Critical Determinant of Amyloid-beta Peptide Length

Huntington Potter, University of Colorado Denver, USA
Short Talk: Use of Parabiosis to Investigate the Role of Apolipoprotein E as Amyloid Catalyst and Peripheral Sink in Alzheimer’s Disease

09:20—09:40
Coffee Break

Longs Peak Foyer
11:30—13:00
Poster Setup

Longs Peak
11:30
On Own for Lunch and Recreation

13:00—22:00
Poster Viewing

Longs Peak
16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Sports-Related TBI and CTE
Meeting has ended...abstracts no longer viewable online.

Grays I
Thomas M. Talavage, Purdue University, USA
Neuroimaging of Concussive and Subconcussive Injury: Potential Clinical Application

* Jeffrey T. Barth, University of Virginia Health System, USA
Neuropsychological Assessment of Sports Concussion and CTE: From Dings to Dementia

Ann C. McKee, Boston University / VA Boston Healthcare System, USA
Molecular Neuropathology of Chronic Traumatic Encephalopathy and Encephalomyelopathy

17:00—19:00
ApoE, APP and Tau - Physiology and Pathophysiology
Meeting has ended...abstracts no longer viewable online.

Grays II & III
* Ryan J. Watts, Denali Therapeutics Inc, USA

David M. Holtzman, Washington University, USA
ApoE and apoE Receptors: Influence on Abeta Metabolism

Irene Knuesel, Roche Innovation Center Basel, Switzerland
Modulation of Amyloid and Tau Pathology by the ApoE Receptor Ligand, Reelin

Jürgen M. Götz, University of Queensland, Australia
The Various Modes of Tau Toxicity

Ina Caesar, Mount Sinai Medical Center, USA
Short Talk: Molecular Imaging of ApoE Isoform-Related Protein Conformation Changes in Human Alzheimer Brain

19:00—20:00
Social Hour with Lite Bites

Longs Peak
19:30—22:00
Poster Session 1

Longs Peak

TUESDAY, FEBRUARY 28

07:00—08:00
Breakfast

Longs Peak
08:00—10:40
Classical Approaches to TBI: Metabolic and Axonal Dysfunction
Meeting has ended...abstracts no longer viewable online.

Grays I
* Steven T. DeKosky, University of Virginia, USA

Nick Tustison, University of Pennsylvania School of Medicine, USA
Understanding the Inside of the Black Box: Optimizing Approaches for the Analysis of Diffusion Tensor Imaging and Cortical Maps in TBI

Stephen T. Ahlers, Naval Medical Research Center, USA
Considerations of Long-Term Sequalae in an Animal Model of Blast-Induced Mild Traumatic Brain Injury

Sam Gandy, Mount Sinai Medical Center, USA
Novel Drugs Enhance Cognition and Stimulate Neurogenesis While Reducing Synaptic Generation of Abeta42

Christopher Giza, University of California, Los Angeles, USA
Metabolism, Neural Activation and Plasticity after TBI: A Developmental Perspective

08:00—11:15
Lipid Transport and Metabolism in the Brain and in the Vasculature
Meeting has ended...abstracts no longer viewable online.

Grays II & III
* David M. Holtzman, Washington University, USA

Cheryl Wellington, University of British Columbia, Canada
From Concussion to Dementia: A Key Role for Apolipoprotein E

Peter Tontonoz, University of California, Los Angeles, USA
Control of Brain Metabolism and LDLR Family Expression by LXRs

Gary E. Landreth, Case Western Reserve University, USA
Retinoid X Receptors as Therapeutic Targets in Alzheimer's Disease

Anders Nykjaer, Aarhus University, Denmark
Sortilins in Neuronal Plasticity and Degeneration

Stephanie J. Soscia, Massachusetts General Hospital, USA
Short Talk: Analysis of the ABCA7 Transporter, Brain Lipids, and Alzheimer’s Disease

Celina Zerbinatti, Merck Research Laboratories, USA
Short Talk: Cholesterol Ester Transfer Protein Deficient Polymorphisms Alter CSF Biomarkers and Reduce Alzheimer's Disease-Related Cognitive Impairment in Apolipoprotein E4 Carriers

10:40—11:15
Molecular Biomarker Approach to TBI and CTE I
Meeting has ended...abstracts no longer viewable online.

Grays I
Kaj Blennow, University of Gothenburg, Sweden
CSF Biomarkers of TBI

Theresa Currier Thomas, University of Kentucky, USA
Short Talk: Diffuse Brain Injury Causes Up-Regulation of Thrombospondins in the Rat Thalamus; Implications for a Role in Post-Traumatic Circuit Reorganization?

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15
On Own for Lunch and Recreation

13:00—22:00
Poster Viewing

Longs Peak
16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—17:35
Molecular Biomarker Approach to TBI and CTE II
Meeting has ended...abstracts no longer viewable online.

Grays I
* Ann C. McKee, Boston University / VA Boston Healthcare System, USA

Kevin K. W. Wang, University of Florida, McKnight Brain Institute, USA
Biomarkers for Traumatic Brain Injury, Potential Relevance to Chronic Traumatic Encephalopathy Development

17:00—19:00
Cell Biology and Development
Meeting has ended...abstracts no longer viewable online.

Grays II & III
* Joachim Herz, University of Texas Southwestern Medical Center, USA

Steven J. Burden, New York University Medical Center, USA
An Lrp4-Centric View of Neuromuscular Synapse Formation

Weichun Lin, University of Texas Southwestern Medical Center, USA
Regulation of Synapse Formation and Maturation by ApoE Receptors and Amyloid Precursor Protein

Graham Collingridge, Mount Sinai Hospital, Canada
Just Another Kinase Involved in Hippocampal Long-Term Depression: Implications for AD

Junichi Takagi, Osaka University, Japan
Short Talk: Structural Basis for Peptide Ligand Recognition by LR11/sorLA Vps10p Domain

17:35—19:00
Animal Models of Blast TBI
Meeting has ended...abstracts no longer viewable online.

Grays I
Kevin Kit Parker, Harvard University, USA
Integrin and Rho Signaling in Blast-Induced Brain Injury

Lee E. Goldstein, Boston University, USA
Injury Mechanisms, Neuropathology, and Sequelae in a Murine Blast Neurotrauma Model

Andrew R. Mayer, Mind Research Network, USA
Short Talk: Biomarkers of Increased Diffusion Anisotropy in Semi-Acute Mild Traumatic Brain Injury: A Longitudinal Perspective in Humans

19:00—20:00
Social Hour with Lite Bites

Longs Peak
19:30—22:00
Poster Session 2

Longs Peak

WEDNESDAY, FEBRUARY 29

07:00—08:00
Breakfast

Longs Peak
08:00—11:00
Insights into CTE from Recent Advances in Molecular Pathology of Neurodegenerative Diseases
Meeting has ended...abstracts no longer viewable online.

Grays I
* Lee E. Goldstein, Boston University, USA

Kathryn E. Saatman, University of Kentucky, USA
The Calpain/Calpastatin System in TBI and Chronic Neurodegeneration

David L. Brody, Washington University School of Medicine, USA
Changes in Amyloid Beta Protein Correlate with Neurological Status after TBI

Douglas H. Smith, University of Pennsylvania, USA
TBI: Weapons of a Slow Killer

David K. Menon, University of Cambridge, UK
Short Talk: PiB PET in TBI: Preliminary Results and Neuropathological Correlates

Rachel Bennett, Massachusetts General Hospital, USA
Short Talk: Human Apolipoprotein E4 Accelerates Tau Pathology following TBI in 3xTg-AD Mice

Andrei Irimia, University of California, Los Angeles, USA
Short Talk: Patient-Tailored Longitudinal Quantification of Brain Atrophy in Chronic Traumatic Encephalopathy using Multimodal Neuroimaging

Linda J. Van Eldik, University of Kentucky, USA
Short Talk: A Novel Class of CNS Drugs Administered Hours Post-Injury Alters Pathology Progression and Improves Neurologic Outcomes in Closed Head Injury Models

08:00—11:00
ApoE, ApoE Receptors and Abeta - Synaptic Modulation, Processing and Transport I
Meeting has ended...abstracts no longer viewable online.

Grays II & III
* Eric M. Parker, Synergy Partners R&D Solutions, USA

Ryan J. Watts, Denali Therapeutics Inc, USA
Are ApoE Receptors Viable "Ski Lifts" to the Brain?

Gabriella D'Arcangelo, Rutgers University, USA
Regulation of Dendritogenesis and Spine Formation by Reelin

Joachim Herz, University of Texas Southwestern Medical Center, USA
A Molecular Basis for the Role of ApoE4 in Alzheimer’s Disease

Steve W. Barger, University of Arkansas for Medical Sciences, USA
Short Talk: ApoE/Reelin Receptors are a Point of Convergence for Three Paths to Alzheimer’s Disease

Justin Howard Trotter, University of South Florida Health, USA
Short Talk: Coordinated Regulation of Dab1 by Fyn and Cdk5

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Experimental Therapeutic Approaches to TBI/CTE Based on Insights from Recent Advances in Molecular Pathology of Neurodegenerative Diseases
Meeting has ended...abstracts no longer viewable online.

Grays I
* Stephen T. Ahlers, Naval Medical Research Center, USA

Milos D. Ikonomovic, University of Pittsburgh, USA
Statin Therapy in Experimental TBI

Mark P. Burns, Georgetown University, USA
Gamma Secretase Inhibitor Therapy in Experimental TBI

Fernando Gomez-Pinilla, University of California at Los Angeles, USA
Diet and Exercise Therapy Against Brain Trauma

Effie Mitsis, James J. Peters VAMC, USA
Short Talk: Resting State Functional Connectivity in Blast-Related Mild Traumatic Brain Injury in OIF/OEF Combat Veterans with and without PTSD

17:00—19:00
ApoE, ApoE Receptors and Abeta - Synaptic Modulation, Processing and Transport II
Meeting has ended...abstracts no longer viewable online.

Grays II & III
* Guojun Bu, Mayo Clinic, USA

John R. Cirrito, Washington University, School of Medicine, USA
Synaptic-Dependent Regulation of Abeta Metabolism and APP Processing in Vivo

Jorge J. Palop, University of California, San Francisco, USA
Neuronal Rhythms, Network Hypersynchrony, and Cognitive Dysfunction in Alzheimer’s Disease

Thomas E. Willnow, Max-Delbrueck-Center for Molecular Medicine, Germany
Role of SORLA/SORL1 in APP Sorting and Alzheimer's Disease

Claus U. Pietrzik, University Medical Center of the Johannes Gutenberg-University, Germany
Short Talk: Genetic Evidence for LRP1 and PrPc Mediated Amyloid-beta Transcytosis Across the Blood-Brain Barrier

19:00—20:00
Social Hour with Lite Bites

Longs Peak

THURSDAY, MARCH 1

07:00—08:00
Breakfast

Longs Peak
08:00—11:00
ApoE and Alzheimer's Disease Session Open to both Meeting Attendees. Therapeutic and Diagnostic Approaches to Neurodegeneration and Metabolism I (Joint)
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Kelly Bales, Pfizer, Inc., USA

Eric M. Parker, Synergy Partners R&D Solutions, USA
Physiologic and Therapeutic Roles of Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1)

Edwin J. Weeber, University of South Florida, USA
Cognition Enhancement by ApoE Receptor Activators

Michael P. Vitek, Duke University Medical Center and Cognosci, Inc., USA
Neuroprotective and Anti-Inflammatory Therapeutics for Traumatic Brain Injury and Alzheimer’s Disease Based Upon Apolipoprotein-E

Mark A. Mintun, Avid Radiopharmaceuticals, Inc., USA
Interaction of Aging, ApoE Genotype and Amyloid Deposition as Revealed by Amyloid Imaging

09:20—09:40
Coffee Break

Longs Peak Foyer
11:00
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
ApoE and Alzheimer's Disease Session Open to both Meeting Attendees. Therapeutic and Diagnostic Approaches to Neurodegeneration and Metabolism II (Joint)
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Eric Reiman, Banner Alzheimer's Institute, USA

Suzanne Craft, Wake Forest University School of Medicine, USA
Insulin Resistance and AD Pathology: Interactions with Apolipoprotein E

Eric R. Siemers, Eli Lilly and Company, USA
Clinical Efficacy of Novel Amyloid-Lowering Therapies

Kelly Bales, Pfizer, Inc., USA
HDAC Inhibition: A Novel Pathway for Modulating Apolipoprotein E Levels

19:00—20:00
Social Hour with Lite Bites

Longs Peak
20:00—23:00
Entertainment

Longs Peak

FRIDAY, MARCH 2

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13NS077709-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Avid Radiopharmaceuticals, Inc.


Eli Lilly and Company


Merck & Co., Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676